Financial Performance - The company's revenue for Q3 2025 was approximately ¥273.70 million, representing a decrease of 38.41% compared to the same period last year[4]. - The total profit for the period was a loss of ¥28.43 million, with a net profit attributable to shareholders of ¥31.12 million, indicating significant financial challenges[4]. - For the first nine months of 2025, the company reported a total revenue of ¥857.21 million, down 39.64% year-on-year, with a net loss of ¥87.24 million[6]. - Total revenue for the first three quarters of 2025 was ¥857,205,461.50, a decrease of 39.7% compared to ¥1,420,111,454.42 in the same period of 2024[23]. - Net loss for the first three quarters of 2025 was ¥79,153,203.33, compared to a net loss of ¥33,512,646.83 in 2024, representing a 135.7% increase in losses[24]. - Operating profit for the first three quarters of 2025 was -¥80,483,168.62, worsening from -¥50,183,819.91 in the same period of 2024[24]. - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.44, compared to -¥0.28 in 2024[25]. Revenue Decline Factors - The company attributed the revenue decline to the transfer of certain subsidiaries and a strategic shift towards optimizing its business structure[6]. - The company is focusing on transforming its traditional medical supply chain services towards medical intelligence, which has impacted revenue and profit margins[6]. Cash Flow and Expenses - Cash flow from operating activities showed a net inflow of ¥54.57 million, reflecting a decrease in cash received from sales and services[5]. - The company has implemented cost control measures, resulting in a reduction of sales, management, and financial expenses by ¥50 million, or 18.54% year-on-year[7]. - In the first three quarters of 2025, the cash inflow from operating activities was CNY 998,060,771.28, a decrease of 38.0% compared to CNY 1,608,884,916.58 in the same period of 2024[27]. - The net cash flow from operating activities was negative at CNY -24,599,514.16, compared to a positive CNY 496,140.58 in the first three quarters of 2024[27]. - The company reported a total cash outflow from operating activities of CNY 1,022,660,285.44, compared to CNY 1,608,388,776.00 in the previous year[27]. Asset and Equity Changes - The total assets at the end of the reporting period were approximately ¥2.09 billion, a decrease of 26.14% from the previous year[5]. - The equity attributable to shareholders increased by 16.78% to ¥1.09 billion compared to the end of the previous year[5]. - Total assets decreased from ¥2,830,070,456.98 in the previous period to ¥2,090,356,280.83, a decline of 26.2%[21]. - The company's equity increased from ¥962,044,094.58 to ¥1,053,305,930.21, an increase of 9.5%[21]. Current Assets and Liabilities - The company reported a total current assets of RMB 1,381,721,482.71 as of September 30, 2025, a decrease of approximately 33.8% from RMB 2,087,128,419.96 on December 31, 2024[19]. - Cash and cash equivalents decreased to RMB 139,610,238.67 from RMB 209,435,589.90, representing a decline of about 33.3%[19]. - Accounts receivable fell to RMB 834,694,092.99, down 35.3% from RMB 1,288,755,013.77[19]. - Inventory decreased to RMB 217,162,250.62, a drop of approximately 33.4% from RMB 326,159,533.80[19]. - Total liabilities decreased from ¥1,868,026,362.40 to ¥1,037,050,350.62, a reduction of 44.4%[21]. Shareholder Information - The company has a major shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holding 10.30% of shares, with 21,642,540 shares[15]. - Shanghai Anze Private Fund Management Co., Ltd. holds 5.76% of shares, totaling 12,100,399 shares[15]. - The company repurchased 3,977,700 shares, accounting for 1.89% of the total share capital as of September 30, 2025[16]. - The company has not reported any significant changes in the participation of major shareholders in margin trading or securities lending[16]. Investment Activities - The company reported an investment income of ¥7,343,276.69 in the first three quarters of 2025, compared to a loss of -¥47,577,734.26 in the same period of 2024[24]. - The cash inflow from investment activities totaled CNY 61,047,772.08, an increase of 87.0% from CNY 32,619,956.30 in the previous year[28]. - The net cash flow from investment activities was CNY 36,083,836.68, significantly up from CNY 7,540,032.26 in the same period last year[28]. - The company received CNY 19,285,848.50 from other investment-related cash activities, slightly up from CNY 18,239,609.15 in 2024[28].

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-093 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于 2025 年前三季度计提资产减值准备的公告 | 项 | 目 | 本期发生额（万元） | | --- | --- | --- | | 信用减值损失 | 应收票据坏账损失 | 0.23 | | | 应收账款坏账损失 | 1,742.49 | | | 其他应收款坏账损失 | 328.58 | | 资产减值损失 | 存货跌价损失 | 76.08 | | 合 | 计 | 2,147.38 | 二、本次计提资产减值准备的相关说明 （一）计提信用减值损失的情况说明 根据《企业会计准则》和公司会计政策相关规定，以预期信用损失为基础， 对各类金融资产按照其适用的预期信用损失计量方法计提减值损失。对信用风险 显著不同的金融资产单项评价信用风险，除了单项评估的金融资产外，公司基于 共同风险特征将金融资产划分为不同的组别，参考历史信用损失经验，结合当前 状况并考虑前瞻性信息，在组合的基础上评估信用风险。 （二） ...

Core Viewpoint - The company reported a significant decline in revenue and incurred net losses in the third quarter and the first three quarters of the year [1] Financial Performance - The company's revenue for the third quarter was 274 million yuan, representing a year-on-year decrease of 38.41% [1] - The net loss for the third quarter amounted to 31.12 million yuan [1] - For the first three quarters, the total revenue was 857 million yuan, reflecting a year-on-year decline of 39.64% [1] - The net loss for the first three quarters reached 87.24 million yuan [1]

Market Overview - The pharmaceutical commercial sector increased by 0.32% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Jianfa Zhixin (301584) closed at 39.29, up 10.18% with a trading volume of 315,400 shares and a transaction value of 1.142 billion [1] - Run Da Medical (603108) closed at 15.30, up 3.66% with a trading volume of 180,900 shares and a transaction value of 274 million [1] - Other notable performers include Huaren Health (301408) up 2.28%, and Saili Medical (603716) up 1.98% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 6.1445 million from institutional investors, while retail investors saw a net inflow of 56.1279 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors increased their positions [2] Individual Stock Capital Flow - Run Da Medical saw a significant net outflow of 49.9539 million from institutional investors, indicating a bearish sentiment [3] - Conversely, Jiuzhoutong (866000) had a net inflow of 16.7641 million from institutional investors, suggesting positive interest [3] - Other stocks like Nanjing Medical (600713) and Huaren Health (301408) also showed varying degrees of net inflows and outflows from different investor categories [3]

Core Viewpoint - The company has completed the registration change and obtained a new business license following the approval of changes in its capital structure and the cancellation of the supervisory board [1][2]. Group 1: Company Changes - The company held its fourth extraordinary general meeting on September 15, 2025, where it approved the proposal to cancel the supervisory board and amend the company's registered capital and articles of association [1]. - As of August 20, 2025, a total of 19,186,941 shares have been converted from the "Saili Convertible Bonds," increasing the total number of shares from 190,952,305 to 210,139,246 [1]. - The company has completed the necessary procedures for the registration change and obtained a new business license from the administrative approval bureau of the Dongxihu District in Wuhan [1]. Group 2: Business License Information - The new business license indicates the company name as "Saili Medical Technology Group Co., Ltd." with a registered capital of 210,139,246 RMB [2]. - The company is classified as a public limited company and is located at 1310 Jinshan Avenue, Dongxihu District, Wuhan [2]. - The business scope includes maintenance and repair of automation equipment, medical device software development, and import/export of medical and biotechnology products, among other activities [2].

Group 1 - The company, Sely Medical, announced the completion of its registered capital change and the filing of its Articles of Association [2] - The company has obtained a new business license from the Administrative Approval Bureau of the Dongxihu District in Wuhan [2]

关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于 2025 年 9 月 15 日召开 2025 年第四次临时股东大会，审议通过了《关于取消监事会、变更公司 注册资本并修订<公司章程>的议案》。因"塞力转债"自 2021 年 3 月 1 日起进 入转股期，公司自 2024 年 4 月 29 日起转股来源全部使用新增股份，自 2024 年 4 月 29 日至 2025 年 8 月 20 日，"塞力转债"累计转股 19,186,941 股。由此， 公司股份总数由 190,952,305 股增加至 210,139,246 股，注册资本相应增加。 塞力斯医疗科技集团股份有限公司 住所：武汉市东西湖区金山大道 1310 号 法定代表人：温伟 注册资本:贰亿壹仟零 ...

Core Insights - The pharmaceutical commercial sector experienced a decline of 1.0% on October 24, with Jianfa Zhixin leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Market Performance - The following companies showed varied performance in the pharmaceutical commercial sector: - Huaren Health (301408) closed at 13.17, up 0.46% with a trading volume of 44,500 shares and a turnover of 58.44 million yuan [1] - Runda Medical (603108) closed at 14.76, up 0.20% with a trading volume of 64,400 shares and a turnover of 95.39 million yuan [1] - Jianfa Zhixin (301584) led the decline, closing at 35.66, down 4.14% with a trading volume of 341,300 shares and a turnover of 1.289 billion yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 259 million yuan from institutional investors, while retail investors contributed a net inflow of 248 million yuan [2] - The following companies had notable capital flows: - Shanghai Pharmaceutical (601607) had a net inflow of 6.9169 million yuan from institutional investors [3] - Baiyang Pharmaceutical (301015) experienced a net inflow of 6.5687 million yuan from institutional investors [3] - Runda Medical (603108) had a net inflow of 3.8868 million yuan from retail investors [3]

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]